Sensitized subjects Sensitized subjects Sensitized subjects Sensitized subjects Non-sensitized control subjects Non-sensitized control subjects Non-sensitized control subjects Non-sensitized control subjects
Group number allergen used in PCBAT Study group description n Age (years, Mean, ±SD) gender (% male) sIgE (KU/L, Mean, ±SD) n Age (years, Mean, ±SD) gender (% male) sIgE (KU/L)
1 Cat Sensitised to cat 18* 41.2 (15.2) 72.2% 12.10 (24.52) 6* 61.0 (21.3) 33.3% <0.4
2 Cat Asthma, on Omalizumab, sensitised to inhalant allergens 4* 45.9 (14.7) 100% 36.05 (47.52) N/A N/A N/A N/A
3 Cat Clinical reactivity quantified with inhaled allergen challenge to cat 17** 38.1(15.6) 52.9% N/A 6* 49.5 (9.9) 33.3% <0.4
4 Peanut Doctor diagnosed peanut allergy (clinical reactivity quantified using oral food challenge for 15 subjects, see OLS for details) 30* 24.5 (7.3) 46.7% 36.99 (38.60) 4* 44.8 (5.1) 50% <0.4
5 Peanut Sensitisation to 1 or more peanut allergen components, but self-reported ingestion indicating oral tolerance 13*** 15.4 (0.9) 69% N/A N/A N/A N/A N/A